Behavioral Design Project Aims to Reduce Benzodiazepine Overuse

Why It Matters

Benzodiazepine overuse drives dependence, falls and cognitive decline; reducing prescriptions improves patient safety and lowers health‑system costs. Demonstrating a replicable, behaviour‑based model could transform deprescribing practices nationwide.

Key Takeaways

• 22% of Spaniards regularly use benzodiazepines, many daily.
• UOC's BDLab applies behavioural design to deprescribing initiative.
• Pilot starts April at Badalona primary‑care centre, three‑month rollout.
• Multi‑dimensional tools include clinician scripts, patient guides, record reminders.
• Successful model could be scaled across Spain’s primary‑care network.

Pulse Analysis

Benzodiazepines, commonly prescribed for anxiety and insomnia, have become a silent epidemic in Spain, with a 2024 OCU study showing that roughly one in five adults uses them regularly and many do so daily. The drugs’ sedative properties raise the risk of dependence, cognitive impairment, falls, and increased health‑care utilization, especially among older patients. Primary‑care physicians, constrained by brief appointments and limited alternatives, often default to these medications, perpetuating a cycle that strains both patients and the public‑health budget.

The UOC’s Behavioural Design Lab (BDLab) leverages evidence‑based behavioural frameworks to break this cycle. By integrating patient education, pharmacist involvement, and environmental nudges—such as electronic‑record reminders and scripted deprescribing conversations—the project targets the cognitive and systemic drivers of overprescribing. The pilot at Badalona’s CAP Martí i Julià centre will distribute clinician toolkits, patient brochures, and sleep‑hygiene resources, while tracking prescription data over a three‑month period. Early research published in Implementation Science Communications indicates that such multi‑dimensional, theory‑informed interventions achieve more sustained reductions than single‑focus approaches.

If the pilot demonstrates measurable declines in long‑term benzodiazepine use, the model could be rolled out to other BSA clinics and beyond, aligning with Spain’s Choosing Wisely and AQuAS Essencial initiatives. Scaling would support UN Sustainable Development Goal 3 by promoting safer medication practices and reducing low‑value care. Moreover, the project offers a template for applying behavioural design to other entrenched prescribing habits, potentially reshaping primary‑care quality improvement across Europe.